Browse the evidence

Tirzepatide's dual GIP/GLP-1 receptor agonism provides a synergistic mechanism that enhances weight loss and mitigates gastrointestinal side effects compared to selective GLP-1 agonists.

Tirzepatide works differently than semaglutide by activating both GIP and GLP-1 receptors. This dual action may lead to greater fat loss and potentially fewer stomach side effects.

GLP-1 and GIP receptor agonists improve obstructive sleep apnea (OSA) severity, with tirzepatide being the first medical therapy approved for OSA, showing significant reductions in apnea-hypopnea index (AHI).

Tirzepatide is the first FDA-approved medical therapy for OSA, showing significant improvements in sleep apnea severity (AHI) in patients with obesity. This benefit occurs both in patients using CPAP and those not using it. It offers a new treatment option for those struggling with OSA, potentially reducing the burden of the disease.

Triple-agonist GLP-1/GIP/Glucagon analogs (e.g., retatrutide) produce superior weight loss compared to dual or single agonists by synergistically activating multiple satiety and energy expenditure pathways.

Newer 'triple-agonist' weight loss medications target three different hormonal pathways (GLP-1, GIP, and Glucagon) instead of just one. Clinical trials show these can lead to over 20% body weight loss, which is significantly higher than older single-target drugs. These are currently experimental and not yet widely available for general use.

Lixisenatide, high-dose canagliflozin (300 mg/day), empagliflozin, and dapagliflozin are associated with a reduced risk of acute kidney injury compared to control treatments.

If you are taking lixisenatide, high-dose canagliflozin, empagliflozin, or dapagliflozin, you may have a lower risk of acute kidney injury compared to those not on these medications. Continue to follow your doctor's recommendations for kidney function monitoring, as these benefits do not eliminate the need for standard care.

Tirzepatide (10 mg and 15 mg) significantly improves health-related quality of life (HR-QoL) in Japanese adults with obesity disease compared to placebo over 72 weeks.

For Japanese adults with obesity disease, treatment with tirzepatide (10 mg or 15 mg weekly, escalated from 2.5 mg) alongside lifestyle changes significantly improves quality of life, particularly physical function and psychosocial well-being, compared to placebo over 72 weeks.

Low-carbohydrate diets improve cardiovascular risk markers (triglycerides, HDL, blood sugar, inflammation) and reduce 10-year ASCVD risk scores, despite potential increases in LDL-C in lean individuals.

If you are on a low-carbohydrate diet, expect improvements in triglycerides, HDL, and blood sugar. If your LDL-C rises, discuss with your provider whether it correlates with other risk factors, as overall cardiovascular risk may still decrease.

A non-carbohydrate counting (non-CC) meal bolus strategy based on preprandial glucose levels, when used with open-source automated insulin delivery (AID), significantly improves time in range (TIR) and reduces glycemic variability compared to manual open-loop modes in adults with Type 1 Diabetes.

If you have Type 1 Diabetes and find carbohydrate counting stressful or error-prone, consider using an open-source automated insulin delivery system (like AndroidAPS) with a simplified bolus strategy. Instead of counting carbs, you calculate your insulin based on your pre-meal glucose level and your average mealtime insulin needs. This approach can significantly improve your time in range and reduce glycemic variability, especially at night, without increasing the risk of hypoglycemia. It is a viable alternative for those who find traditional carb counting burdensome.

Intensive lifestyle interventions (ILI) involving caloric restriction and physical activity cause a significant increase in 25-hydroxyvitamin D [25(OH)D] and suppress parathyroid hormone (PTH) elevation during the period of maximal weight loss in adults with type 2 diabetes.

If you have type 2 diabetes and are losing weight through diet and exercise, expect your Vitamin D levels to rise and your Parathyroid Hormone (PTH) to decrease, especially in the first year. This is a normal and likely beneficial response to weight loss, though it may normalize over time. Monitor your bone health as weight loss can also lead to bone loss.

Intermittent fasting significantly improves lipid profiles by reducing total cholesterol and LDL, but may temporarily increase triglycerides in short-term interventions (≤ 12 weeks).

Intermittent fasting improves total cholesterol and LDL, key markers for heart health. However, be aware that triglycerides may temporarily rise in the first 12 weeks as your body adapts. This is often a transient phase. If you have high baseline triglycerides, consult a healthcare provider and consider longer-term adherence to see the full lipid benefits.

Intermittent fasting significantly reduces diastolic blood pressure but has no significant effect on systolic blood pressure, fasting plasma glucose, or HbA1c in overweight and obese adults.

Intermittent fasting can help lower diastolic blood pressure, a key component of heart health. However, it may not significantly affect systolic blood pressure or blood sugar levels (FPG, HbA1c) in the short term. For comprehensive cardiometabolic health, combine IF with other lifestyle interventions and monitor your specific markers.

Intermittent fasting downregulates enteroendocrine signaling, specifically GLP-1, GCG, and PYY, while upregulating PPAR-α, which correlates with improved lipid profiles.

The molecular changes observed (PPAR-α upregulation, GLP-1 downregulation) suggest that IF works by altering how your body processes fats and regulates hormones, not just by restricting calories. This may inform future targeted therapies.

Semaglutide improves glycemic control and metabolic parameters in patients with Type 2 Diabetes and obesity.

For those with Type 2 Diabetes, semaglutide helps manage blood sugar and aids in weight loss, though the weight loss effect may be more modest compared to non-diabetic patients.

Semaglutide at its maximum tolerated dose (MTD) is associated with the highest odds of treatment discontinuation due to adverse events among all tested regimens, including tirzepatide MTD.

If you choose semaglutide at its maximum dose, be aware that you have the highest statistical risk of stopping the medication due to side effects compared to other options in this study. Monitor your tolerance closely and communicate with your provider immediately if side effects become unmanageable.

Use of GLP-1 receptor agonists (GLP1-RAs) is not associated with an increased risk of thyroid cancer compared to DPP-4 inhibitors in patients with type 2 diabetes.

If you have type 2 diabetes and are considering a GLP-1 medication like Ozempic or Wegovy, current large-scale evidence suggests it does not increase your risk of thyroid cancer compared to other common diabetes drugs. While rodent studies showed thyroid effects, this has not been observed in human population studies.

GLP-1 receptor agonists (GLP-1 RAs) significantly increase the risk of gastrointestinal adverse events, specifically intestinal obstruction and perioperative aspiration, due to delayed gastric emptying.

If you are taking a GLP-1 medication (like Ozempic or Wegovy) and have surgery or an endoscopy, tell your medical team. You may need to adjust your fasting time or pause the medication to prevent stomach contents from entering your lungs, which is a known risk of these drugs.

GLP-1 receptor agonists are associated with an increased risk of gallbladder and biliary tract diseases, particularly with weight-loss focused dosing and specific agents like liraglutide.

Be aware that GLP-1 medications can increase the risk of gallstones, especially if you are losing weight rapidly. Report any abdominal pain to your doctor. This risk is higher with weight-loss doses compared to diabetes doses.

Current evidence does not support a significant increased risk of acute pancreatitis or pancreatic cancer associated with GLP-1 receptor agonists in human populations, despite early animal studies and spontaneous reports.

You do not need to worry about developing pancreatitis or pancreatic cancer from GLP-1 medications. Large studies have confirmed they are safe in this regard, although you should stop the medication if you experience severe abdominal pain.

Polygenic scores for BMI and Type 2 Diabetes do not significantly predict weight loss outcomes in patients treated with GLP-1 receptor agonists.

If you are taking a GLP-1 RA (like semaglutide or liraglutide), your common genetic risk for obesity does not predict how much weight you will lose. The drug's effectiveness is largely independent of your polygenic score for BMI or Type 2 Diabetes. Focus on adherence and lifestyle factors rather than genetic testing for treatment selection.

GLP-1 RA treatment results in significantly lower weight loss in individuals of African and admixed American ancestry compared to European ancestry, after adjusting for baseline factors.

If you are of African or admixed American ancestry, you may experience slightly less weight loss from GLP-1 RA drugs compared to European ancestry individuals, even when adjusting for baseline weight and other factors. This may be due to biological or socioeconomic factors. Close monitoring and potential dose adjustments may be necessary.

GLP-1 receptor agonists (GLP-1RAs) induce pre-ingestive, cognitive satiation by activating dorsomedial hypothalamus (DMH) GLP-1R neurons, which inhibit arcuate nucleus AgRP neurons to terminate meals before ingestion begins.

GLP-1 medications work partly by changing how your brain processes food cues before you even eat. By activating specific brain regions (DMH), they signal 'stop' based on anticipation, not just stomach fullness. This cognitive effect helps reduce meal size and frequency, contributing to weight loss beyond just slowing digestion.

Multi-receptor incretin drugs are associated with an increased risk of adverse events (primarily gastrointestinal) compared to placebo, but do not significantly increase the risk of serious adverse events.

Be aware that multi-receptor incretin drugs commonly cause gastrointestinal side effects like nausea, which may lead to discontinuation for some. However, the risk of serious health events is not significantly higher than placebo. Discuss potential side effects with your doctor and report any severe or persistent symptoms.

Obesity increases the risk of various cancers, including breast, endometrial, ovarian, kidney, thyroid, and gastrointestinal cancers, through mechanisms involving chronic inflammation, adipokine secretion, and epigenetic dysregulation.

Obesity increases your risk of several types of cancer, including breast, endometrial, and gastrointestinal cancers. This risk is driven by chronic inflammation and hormones secreted by fat tissue.

Endogenous gut-derived GLP-1, secreted in response to nutrients or non-caloric stimuli (like gastrointestinal distension), regulates feeding behavior and glucose metabolism via vagal sensory nerves without causing the adverse effects (nausea/vomiting) associated with GLP-1 receptor agonists.

You can influence your GLP-1 levels naturally. Eating GLP-1-stimulating foods (meat, fish, salad) first, followed by a wait before carbs, improves glycemic control and weight loss. Gastrointestinal distension from bulky, low-energy-density foods also triggers beneficial GLP-1 secretion via vagal nerves without causing nausea.

Preoperative use of GLP-1 receptor agonists does not improve long-term weight loss, diabetes remission, or surgical safety outcomes in patients undergoing metabolic bariatric surgery compared to those who do not use GLP-1s.

If you are considering bariatric surgery, using GLP-1 drugs (like Ozempic or Wegovy) beforehand does not appear to make your surgery more successful or your weight loss better in the long run. In fact, it may just delay getting the more effective surgical treatment. If you are experiencing side effects from these drugs or they aren't working well enough, switching to surgery is a valid and effective path, but don't expect the drugs to give you a 'head start' on your results.